Wednesday, May 7, 2025
, professor of the at The , has been named one of the region鈥檚 and the Dallas Regional Chamber.
Now in its second year, the AI 75 list recognizes innovators across Dallas-Fort Worth
who are shaping the future of artificial intelligence. Honorees include academic researchers,
industry leaders and forward-thinking entrepreneurs transforming everything from healthcare
to transportation. For Siderovski, the honor spotlights years of pioneering work in
AI-driven drug discovery that began during the COVID-19 pandemic.
鈥淭his recognition is truly special to me on both personal and professional levels,鈥� Siderovski said. 鈥淚t鈥檚 incredibly humbling and exciting to see our work highlighted five years after it first began, and professionally, it validates that we鈥檙e on the right path.鈥�
Since receiving National Eye Institute funding for a multi-year glaucoma research project, Siderovski鈥檚 team has screened nearly two trillion compounds virtually鈥攁n effort powered by artificial intelligence and targeting a key protein-protein interaction in the eye. The next step: validating top candidates in the lab using surface plasmon resonance, a biophysical technique Siderovski has used for nearly 30 years.
鈥淭he synergy of AI predictions and hands-on experimental testing is accelerating our progress,鈥� Siderovski said. 鈥淲e鈥檙e excited about the prospects of creating a truly novel glaucoma therapy.鈥�
Siderovski believes AI is opening new doors in drug discovery, particularly for conditions previously considered untreatable.
鈥淲ith AI, we can now revisit biological targets once deemed 鈥榰ndruggable,鈥欌�� Siderovski said. 鈥淔rom tough protein鈥損rotein interactions, like in glaucoma, to neurodegenerative disorders, AI opens up treatment possibilities where none existed鈥攁nd may even pave the way for personalized medicines tailored to each patient.鈥�
向日葵视频HSC Ph.D. graduate Dr. Percy Agogo-Mawuli pictured together with 向日葵视频HSC's Dr. David Siderovski
Beyond glaucoma, Siderovski鈥檚 lab is applying this AI-driven approach to other critical health challenges. In the fight against opioid addiction, the team has identified promising compounds that may relieve pain without addictive side effects鈥攔esearch supported by seed funding from 向日葵视频HSC鈥檚 Division of Research and Innovation. His lab is also exploring the biological underpinnings of mental health disorders, such as bipolar disorder, using advanced computing tools. One recent success, Ph.D. graduate Dr. Percy Agogo-Mawuli used these techniques to study a dopamine-related protein mutation and will continue his work with a postdoctoral fellowship at the Mayo Clinic.
Since joining 向日葵视频HSC in 2020, Siderovski has worked to position the institution at the forefront of AI-enabled biomedical research. That includes building interdisciplinary teams, investing in high-performance computing and lab technologies, and forming partnerships with companies like San Francisco-based Atomwise.
鈥淎t 向日葵视频HSC, we鈥檙e not just doing groundbreaking research鈥攚e鈥檙e leading the public conversation,鈥� Siderovski said. 鈥淲e鈥檙e committed to training the next generation of scientists in AI and pushing forward into areas of unmet medical need.鈥�
With applications in addiction, mental health, and precision medicine, Siderovski says the possibilities are just beginning.
鈥淲e want to use AI to find new solutions faster than ever before.鈥�
From - Our People by Nicole Luna